Citamet

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Citamet

Understanding Citamet

Citamet is a combination oral medication used in the management of type 2 diabetes mellitus. It contains two active pharmacological agents that work through different mechanisms to help control blood sugar levels: metformin hydrochloride and sitagliptin.

Active Components

  • Sitagliptin: This component belongs to a class of medications known as dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the levels of natural substances called incretins. Incretins help control blood sugar by increasing insulin release, especially after meals, and decreasing the amount of sugar produced by the liver.
  • Metformin: A member of the biguanide class, metformin improves glycemic control by enhancing insulin sensitivity in peripheral tissues, decreasing glucose production in the liver, and reducing the absorption of glucose in the intestines.

Therapeutic Intent

The primary purpose of Citamet is to assist adults with type 2 diabetes in maintaining healthy blood glucose levels. It is typically utilized when a single medication, alongside diet and exercise, does not provide sufficient glycemic control. By combining two medications with complementary modes of action, Citamet addresses multiple physiological factors that contribute to elevated blood sugar.

Characteristics of Type 2 Diabetes

Type 2 diabetes is a chronic condition where the body does not use insulin properly or cannot produce enough insulin to maintain normal glucose levels. Over time, poorly managed blood sugar can lead to various health complications. Citamet is designed to be part of a comprehensive management plan to stabilize these levels, though it is not used for the treatment of type 1 diabetes.

Regulatory References

  1. National Library of Medicine (NIH)
  2. StatPearls

What side effects are possible with Citamet?

The possible side effects and safety characteristics of Citamet (Cimetidine) are officially classified across several System-Organ Classes (SOC) in regulatory documents, with occurrences grouped by frequency (e.g., Very Common, Common, Rare).

Frequency-Classified Adverse Reactions

Adverse reactions that are considered Common (ge 1% to 10%) in the official safety profile include headache, mild diarrhea, dizziness, somnolence (drowsiness), and rash. A small, reversible increase in plasma creatinine levels, which does not signify deteriorating renal function, is documented as Very Common.

System-Organ-Class Groupings

The most frequently reported effects involve the Gastrointestinal System (e.g., diarrhea) and the Nervous System (e.g., headache, somnolence). Other systems affected include the Endocrine System (e.g., gynecomastia, reversible impotence), Hepatobiliary (e.g., elevated liver enzymes, rare hepatitis), and Blood and Lymphatic System (e.g., rare leukopenia, thrombocytopenia, and very rare agranulocytosis).

Serious and Contextual Safety Notes

The regulatory profile documents rare but serious adverse events, such as reversible confusional states (mental confusion, agitation, hallucinations), which are reported predominantly in severely ill patients and older adults. Cardiovascular effects (e.g., sinus bradycardia, AV heart block) and severe skin reactions are reported rarely. Specific Population Safety Notes include the increased risk of CNS effects in patients with renal impairment. Time-related patterns state that certain endocrine effects like gynecomastia and reversible impotence are associated with long-term exposure (e.g., 1 month or longer, or high doses for ge 12 months, respectively) and that CNS effects typically develop within two to three days of initiation. Most documented adverse reactions are reported to be reversible upon withdrawal of the drug.

Overdose and Emergency Response

Overdose and when to seek help

Citamet overdose is a serious medical event with the potential for life-threatening complications, particularly lactic acidosis. This condition involves a critical buildup of lactic acid in the blood, which requires immediate and specialized treatment.

Clinical Manifestations

Initial overdose symptoms are often non-specific and may include severe nausea, vomiting, diarrhea, and stomach pain, followed by profound tiredness, muscle pain, and unusual drowsiness. More severe presentations can involve trouble breathing (deep, rapid respirations), dizziness, lightheadedness, a decrease in body temperature, and an abnormally fast or slow heartbeat.

When to Seek Urgent Medical Attention

If an overdose of Citamet is suspected, immediate emergency medical help must be sought. Do not wait for symptoms to worsen. Due to the potential for delayed onset of severe lactic acidosis, prompt evaluation is necessary even if the individual initially appears well.

Contact emergency services or a poison control center right away if you or someone else has taken more than the prescribed amount. Hospital management of an overdose focuses on supportive care, correcting the severe metabolic imbalance, and may include treatments like hemodialysis to remove the drug from the bloodstream, especially in cases of severe acidosis or in patients with impaired kidney function.

Therapeutic Uses of Citamet

Main Therapeutic Uses

Citamet is a combination medication primarily used in the management of type 2 diabetes mellitus. It combines two different blood-glucose-lowering agents with complementary mechanisms of action to help patients achieve better glycemic control when a single medication is insufficient.

Type 2 Diabetes Management

The medication is indicated for adults with type 2 diabetes to improve blood sugar levels. It is used as an adjunct to diet and exercise. Type 2 diabetes is a chronic condition where the body does not use insulin properly or cannot make enough insulin, leading to elevated levels of glucose in the bloodstream.

Dual Mechanism of Action

Citamet works through two distinct pathways to manage blood sugar:

  • Reduction of Glucose Production: One component acts primarily by decreasing the amount of glucose produced by the liver and improving the body's sensitivity to insulin.
  • Enhancement of Natural Insulin Response: The second component helps increase the levels of natural substances called incretins. These substances increase insulin release, particularly after eating, and decrease the amount of sugar the liver produces.

Clinical Benefits

By addressing multiple physiological factors, the combination therapy provides several clinical advantages for the long-term management of diabetes.

Glycemic Control

The primary benefit of this treatment is the stabilization of blood glucose levels. Maintaining glucose levels within a target range is essential for reducing the risk of long-term complications associated with high blood sugar.

Hemoglobin A1c Reduction

Regular use of this medication helps in lowering Hemoglobin A1c (HbA1c) levels. HbA1c is a marker that reflects average blood sugar levels over a period of two to three months, serving as a key indicator of how well the diabetes is being managed.

Postprandial and Fasting Glucose

The combination is effective in managing both fasting blood glucose (sugar levels after not eating for several hours) and postprandial blood glucose (sugar levels after meals). This comprehensive coverage helps prevent the sharp spikes in blood sugar that can occur throughout the day.

Regulatory References

  1. Official NIH DailyMed labeling for Cimetidine

Eligibility and Restrictions for Use

Who Can and Cannot Use Citamet?

Citamet, a medication primarily used to manage symptoms related to certain gastrointestinal conditions, is generally safe for many adult patients. However, its use is guided by specific medical indications and contraindications to ensure patient safety and maximize therapeutic benefit.

General Recommendations for Use

Who Can Generally Use Citamet? Conditions
Adults For approved uses, typically including the treatment of stomach and duodenal ulcers, gastroesophageal reflux disease (GERD), and conditions associated with excessive stomach acid production (e.g., Zollinger-Ellison syndrome).
Pediatric Patients Use in children is generally not recommended unless specifically prescribed and carefully monitored by a specialist due to limited data on safety and efficacy in this population.

Contraindications (Who Should Not Use Citamet)

Citamet is generally contraindicated and should not be used by individuals with a known hypersensitivity or allergy to the drug or any of its components.

Additionally, caution is advised, and alternative treatment options may be necessary for patients with pre-existing conditions, including significant kidney impairment or liver disease, as these conditions can affect how the drug is processed and eliminated by the body. A healthcare provider must evaluate the risk-benefit profile before prescribing Citamet to these vulnerable populations. Always consult a healthcare professional to determine if Citamet is appropriate for your specific health profile.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Citamet’s interaction profile is based on its capacity to affect the systemic concentration of other medications through two primary pharmacokinetic processes, as documented in regulatory labeling.

Interaction Type Examples of Affected Medicines
Metabolic Inhibition Warfarin, Theophylline, Phenytoin
Transporter Inhibition Procainamide, Metformin

The inhibition of certain Cytochrome P450 enzymes and competition for renal tubular secretion result in increased plasma levels and reduced clearance for co-administered drugs like Warfarin and Procainamide. Co-administration is formally contraindicated with certain drugs, including Dofetilide and Pimozide, due to the risk of severe outcomes such as prolonged QTc interval resulting from Cimetidine's interference with their clearance.

Cimetidine's therapeutic effect of increasing gastric pH affects drug absorption, mandating timing separation for medications such as Ketoconazole and Antacids (must be administered 2 hours before Cimetidine) to ensure proper bioavailability. The risk of interaction-related drug accumulation, which may result in effects like reversible confusional states, is specifically noted in regulatory documents for the elderly or individuals with pre-existing renal or hepatic disease.

Mechanism of Action

Citamet is an oral medication that modulates the incretin hormone pathway, a key component of glucose homeostasis. Its action is focused on two key mechanistic domains.


Inhibiting the DPP-4 Enzyme

This domain describes the drug's primary molecular target and immediate effect: Citamet works by selectively inhibiting the Dipeptidyl Peptidase-4 (DPP-4) enzyme . Blocking this enzyme prevents the rapid breakdown and inactivation of natural gut hormones called incretins, resulting in higher, sustained active concentrations of incretins in the plasma.


Glucose-Dependent Hormone Modulation

This domain covers the resulting systemic effect and physiological consequence: The preserved incretin hormones amplify signaling to the pancreas, leading to increased insulin secretion and suppressed glucagon secretion in a manner that is dependent on the presence of high glucose levels. This coordinated effect reduces hepatic glucose production and alters the dynamics of glucose movement in the body.

Dosage and Administration Information

How to Use Citamet

Citamet, containing the active ingredient Cimetidine, is administered via three approved methods: oral (using tablets or a solution), intravenous (IV), and intramuscular (IM) injection. The specific route and dose are determined by the treating professional, but all regimens adhere to the overall limitation that the total daily dosage must not exceed 2400 mg.

Standard Regimens and Frequency

Oral use follows set patterns. For acute conditions, a common approach is taking 800 mg once daily at bedtime, though alternatives include 400 mg twice daily or 300 mg four times daily. For long-term maintenance after initial healing, a reduced oral dose, often 400 mg once daily at bedtime, is used over an extended period. The four-times-daily oral dose is generally taken with meals and at bedtime.

When parenteral administration is necessary, the standard intermittent dose is 300 mg given every 6 to 8 hours. Intravenous administration requires dilution of the injectable solution and must be given slowly, with the infusion lasting 15 to 20 minutes. Antacids should not be taken simultaneously with oral Cimetidine, as this may interfere with absorption.

Population-Specific Instructions

Specific adjustments are required for certain populations. Patients with significantly impaired renal function (Creatinine Clearance less than 30 mL/min) require a dose reduction or an extended dosing interval, such as 300 mg every 12 hours. For pediatric use (children over one year), the approved oral dosing is weight-adjusted at 25 to 30 mg/kg per day in divided doses.

Recent Clinical Evidence

Research evidence / Overview of studies for Citamet

This overview describes the types of scientific research that have explored outcomes related to Citamet (cimetidine) for various acid-related conditions, focusing only on the structure of the evidence and areas of uncertainty, without offering medical advice or making claims about individual outcomes.


Evidence for the Management of Active Ulcers

The foundational research exploring Citamet in contexts involving conditions characterized by fluctuating or episodic manifestations, such as active duodenal ulcers, was primarily established through short-term randomized controlled trials and multicenter, double-blind studies. Researchers examined populations of adults. The primary measured outcomes included the endoscopic evaluation of outcomes related to inflammatory or irritative states and patient-reported outcomes describing perceived discomfort. The research provides insight into short-term changes measured during the study period. However, the follow-up durations were limited, and the research provides context but not individual predictions regarding long-term ulcer status.

Research on Preventing Ulcer Recurrence (Maintenance)

The research exploring continued administration of Citamet for conditions presenting with cycles of stability and flare-ups, relied on placebo-controlled maintenance trials and long-term observational follow-up studies that examined the relationship between continued administration and subsequent ulcer occurrence. The primary outcomes related to systemic or functional imbalance measured were patterns of subsequent ulcer occurrence. The research describes observations where the subsequent ulcer occurrence rate was reported to vary when the medicine was evaluated in the maintenance studies compared to control groups. These studies contribute to the broader evidence landscape by describing patterns related to occurrence.

What is Still Uncertain About the Research for Citamet

The existing research structure highlights several areas where certainty remains low. For many common conditions, comparative evidence is lacking against newer drug classes (such as PPIs) that have since become standard treatments. Furthermore, data for certain groups remain insufficient, meaning subgroup findings are uncertain for specific populations. The results apply only to the populations studied, and the findings were mixed when research explored outcomes in complex or unique patient situations.

Key Studies & References

  1. Recurrent ulcer after successful treatment with cimetidine or antacid
  2. Efficacy of different doses of cimetidine in the treatment of reflux esophagitis. A review of three large, double-blind, controlled trials
  3. CIMETIDINE TABLETS, USP - DailyMed (Full Prescribing Information/Professional Label)

Frequently Asked Questions (FAQ)

Common questions about Citamet (FAQ)

Q: What is the main medical purpose of Citamet?

According to official product information, Citamet is used to treat conditions related to excess stomach acid. These uses include the treatment of ulcers, Gastroesophageal Reflux Disease (GERD), and managing specific conditions like Zollinger-Ellison syndrome. The over-the-counter (OTC) form is used to help prevent and treat heartburn.

Q: What class of medication does Citamet belong to?

Citamet is classified as a Histamine H2-receptor blocker (or H2 blocker). This means the drug works by competing with histamine to block certain receptors. This action ultimately decreases the amount of acid made by the stomach.

Q: How does the official labeling describe what Citamet treats?

Official labeling describes the drug's approved uses, including the short-term treatment of duodenal and gastric ulcers. It is also indicated for the management of reflux esophagitis disease. Additionally, its uses extend to the prevention of certain types of stress-related gastric ulcers.

Q: How long does it typically take to feel the effects of Citamet?

Studies have examined the time it takes for the drug to begin working. The onset of action for the active ingredient is generally listed as approximately one hour after administration. This is when the medication starts significantly reducing gastric acid production.

Q: What is the usual duration of effect for a single dose of Citamet?

Regulatory data indicates that a single dose has been shown to result in a significant reduction in gastric acid secretion for a period of about four to five hours.

Q: What happens if Citamet does not seem to be working?

Official over-the-counter (OTC) warnings provide guidance on what to do if symptoms persist. They advise patients to stop use and notify a healthcare provider if heartburn continues or worsens, or if stomach pain does not improve.

Q: What is the research evidence for the main use of Citamet?

Evidence supports the drug's use for its labeled purposes. Studies indicate its effectiveness in the management of peptic ulcer disease, gastroesophageal reflux disease, and gastric hypersecretion.

Q: What are the most common side effects of Citamet reported in regulatory documents?

According to regulatory documents, the most common reported side effects (affecting approximately 1% to 10% of users) include headache, dizziness, drowsiness (somnolence), and diarrhea.

Q: How long do common side effects when starting Citamet usually last?

Information from official sources indicates that some common Central Nervous System (CNS) effects, such as reversible confusional states, usually clear within three to four days of stopping the medication. The duration of milder, common effects like headache can vary among individuals.

Q: Are there any serious or rare adverse events associated with Citamet?

Official documents list reports of rare, serious adverse events. These have included blood disorders like agranulocytosis, kidney issues like interstitial nephritis, and severe reactions like anaphylaxis (a serious allergic reaction).

Q: Is it normal to experience mild nausea when first taking Citamet?

Regulatory over-the-counter (OTC) warnings list nausea or vomiting as a symptom that requires consultation with a healthcare provider before using the drug. This indicates that symptoms like nausea should be discussed with a healthcare professional before use.

Q: Can Citamet cause fatigue or drowsiness?

Official product information reports that drowsiness (somnolence) is a commonly observed side effect. This has been reported in approximately 1 in 100 users.

Q: Is weight gain or weight loss a known side effect of Citamet?

The over-the-counter (OTC) labeling includes unexplained weight loss as a symptom that should be discussed with a doctor before using the product. Regulatory information notes unexplained weight loss as a symptom that requires consultation with a doctor before using the product.

Q: What body systems are most frequently affected by Citamet side effects?

Adverse event information in official documents is typically organized by major body systems. Side effects are most commonly reported in the Gastrointestinal, Central Nervous System (CNS), Endocrine, Hematologic, and Hepatobiliary systems.

Q: What signs or symptoms are listed as reasons to seek medical attention while using Citamet?

Official OTC warnings specify signs that warrant immediate attention from a healthcare professional. These include trouble or pain swallowing food, vomiting with blood, or observing bloody or black stools.

Q: Are there known long-term side effects associated with Citamet use?

Adverse events reported with use lasting ge 1 month have included gynecomastia (enlargement of male breast tissue). Official reports also note that prolonged treatment (e.g., ge 2 years) has been associated with the potential development of Vitamin B12 deficiency.

Q: What is a known contraindication for taking Citamet?

A major condition listed as a contraindication is a known hypersensitivity (allergy) to the active ingredient, cimetidine, or any other component of the formulation. If you have a known allergy to similar drugs, this should be discussed with a healthcare professional.

Q: Can Citamet cause allergic reactions?

Regulatory documents report that rare cases of allergic reactions have occurred. These reactions have included severe forms such as anaphylaxis and hypersensitivity vasculitis. Patients should be aware of the signs of an allergic reaction.

Q: Are there known interactions between Citamet and alcohol?

Official warnings state that patients should avoid alcoholic beverages while using the product. Regulatory warnings state that alcohol may increase drowsiness when combined with the medication.

Q: Does Citamet interact with common over-the-counter pain relievers like ibuprofen?

Regulatory information advises consulting a doctor or pharmacist if taking any prescription drug. This is because acid reducers may interact with certain medications, including those sold over the counter. This guidance is in place to prevent potential effects on the effectiveness or safety of either drug.

Q: Is it safe to take herbal supplements, such as St. John's Wort, with Citamet?

General regulatory guidance suggests discussing the use of any supplements or herbs with a healthcare provider. This precaution is advised due to the potential for interactions that could affect the medication’s safety or effectiveness.

Q: What categories of prescription drugs have documented interactions with Citamet?

Regulatory information and medical literature document known interactions with certain categories of prescription drugs. These include drugs like warfarin (a blood thinner), theophylline (an asthma drug), and phenytoin (a seizure drug). These interactions are typically due to the drug's effect on certain liver enzymes.

Q: Is grapefruit juice specifically mentioned as an interaction risk with Citamet?

While specific product labels may not always mention it, general drug interaction reviews may note that grapefruit can affect certain drug metabolism pathways. Grapefruit may potentially increase blood levels of certain interacting drugs.

Q: Can Citamet interact with common vitamin supplements?

Official reports note that prolonged use (e.g., ge 2 years) is associated with the potential for Vitamin B12 deficiency due to malabsorption. This represents a known drug-vitamin relationship that should be monitored.

Q: Are there any dietary restrictions mentioned in the drug information for Citamet?

Official patient information advises avoiding foods like rich, spicy, fatty, and fried foods, as well as caffeine and alcohol. These restrictions are advised because such items can contribute to or worsen heartburn symptoms.

Q: What happens if Citamet is taken with another drug that also causes drowsiness?

Regulatory warnings state that other drugs that cause drowsiness, such as sedatives and tranquilizers, may increase drowsiness when used with this product.

Q: Are there special considerations for older adults (seniors) using Citamet?

Official warnings advise caution in older adults due to the increased potential for confusion and Central Nervous System (CNS) effects. It is noted that the drug may be avoided in individuals at risk of delirium.

Q: What is the official safety classification of Citamet for use during pregnancy?

Regulatory sources assign the drug an FDA Pregnancy Category B. This classification indicates that animal studies have generally failed to show a risk to the fetus.

Q: Is Citamet considered safe to use while breastfeeding, according to regulatory sources?

Official information advises to ask a health professional before use while breastfeeding. This is because the active ingredient does enter breast milk in small amounts.

Q: Can people with pre-existing liver problems use Citamet?

Regulatory warnings state that the medication should be used with caution in patients with liver disease. This is because the drug is partially metabolized by the liver, and liver disease increases the risk of Central Nervous System (CNS) toxicity.

Q: What medical conditions are listed as absolute reasons not to use Citamet?

In addition to known allergy, the official label for OTC use lists certain pre-existing conditions as reasons to consult a healthcare provider before use. These include frequent chest pain, unexplained weight loss, and stomach pain.

Q: What is the typical stability and proper storage condition described for Citamet?

Official product information advises storing the product at temperatures between 15 C to 30 C (59 F to 86 F). This helps ensure the stability of the medication.

Q: How does food intake affect the way Citamet works?

Official documents indicate that the absorption of the active ingredient is generally little impaired by food or antacids. However, some dosing instructions advise taking the medication with meals. This timing can sometimes be used to help manage symptoms.

Q: Can Citamet be taken with antacids or other acid-reducing medications?

Regulatory warnings for the over-the-counter (OTC) version advise against using it with other acid reducers. For antacids, official information notes that they minimally affect absorption. It is generally recommended to discuss all acid-reducing products with a healthcare provider due to the potential for overlap or interference.

Q: Why do some people experience initial sleepiness when starting Citamet?

Drowsiness (somnolence) is a commonly reported side effect in official documents. Although the specific clinical reason for this effect is not always detailed for patients, it is a known adverse event categorized under Central Nervous System effects.

Q: What does the term 'pharmacodynamics' mean for Citamet in simple language?

Pharmacodynamics describes how the drug affects the body. Regulatory information notes it is a reversible, competitive antagonist of histamine on H2 receptors that ultimately inhibits gastric acid secretion.

How should Citamet be stored and disposed of?

Citamet (Cimetidine) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C. The product must be Protected from light and kept in a tightly closed, light-resistant container as required by regulatory labeling.

All forms of the medication must be stored out of the sight and reach of children; the tablets use a child-resistant closure. The Cimetidine oral solution must be discarded 1 month after first opening the container to ensure stability.

Disposal of unused or expired medicine should utilize an official drug take-back program or adhere to the proper household trash disposal method, which involves mixing the medicine with an undesirable substance before discarding. All disposal must comply with local and national regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Citamet found in:

A-Z Index: